Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma - Wang, Michael L.; Jurczak, Wojciech; Zinzani, Pier Luigi; Eyre, Toby A.; Cheah, Chan Y.; Ujjani, Chaitra S.; Koh, Youngil; Izutsu, Koji; Gerson, James N.; Flinn, Ian; Tessoulin, Benoit; Alencar, Alvaro J.; et al. (Journal of Clinical Oncology, 2023)
Keywords: Adult; Aged; Aged, 80 and over; Humans; Lymphoma, Mantle-Cell; Lymphoma, Mantle-Cell - drug therapy; Lymphoma, Mantle-Cell - pathology; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Recurrence, Local - drug therapy; Pirtobrutinib, Covalent Bruton Tyrosine Kinase Inhibitor, Mantle-Cell Lymphoma; Protein Kinase Inhibitors; Protein Kinase Inhibitors - adverse effects; RAPID COMMUNICATIONS; Tyrosine Kinase Inhibitors